NFL Biosciences

AGM Information • May 31, 2024

NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024

All of the resolutions recommended by the Board of Directors were approved

NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, held its combined general meeting on May 30, 2024 in Montpellier, chaired by Ignacio Faus, Chairman and CEO of NFL Biosciences.

On the date of the general meeting, the total number of shares entitled to voting rights was 9,676,146, for a total of 11,954,015 voting rights. The 29 shareholders presented together held 3,621,823 shares (representing 37.43% of the shares entitled to voting rights) and 5,389,647 voting rights (45.09% of the voting rights). The general meeting deliberated on 21 ordinary and extraordinary resolutions. With the exception of the 18th resolution concerning the company savings plans, which the Board of Directors did not recommend adopting, all of the other resolutions were adopted. Specifically, resolutions 5 to 9 relating to the Directors were approved with 99.9% of the votes and concerned:

Dr Ignacio Faus, Chairman and CEO of NFL Biosciences since February 2023 and Director since May 2021, was reappointed. He has 27 years of experience in large and medium-sized pharmaceutical companies and in private and public biotech companies. In 2006, he co-founded Palau Pharma, a biotech specialized in autoimmune and inflammatory diseases. This company raised more than €50m from international investors and secured six licensing agreements. Palau Pharma was sold in 2013.

Bruno Lafont, Director since May 2021 and Chief Operating Officer, and also co-founder of NFL Biosciences, was reappointed. He is in charge of the structuring and technical development of NFL Biosciences and its various projects. Previously, Bruno Lafont spent 12 years on the management team of PCM, an international French industrial group, as Innovation Director from 1999 to 2004, then as President and in charge of setting up the group's US subsidiary in Houston (Texas) from 2004 to 2009.

Francis Ahner, member of the Board of Directors since May 2021, was reappointed. He is also Honorary President of the International Federation of Intellectual Property Attorneys (FICPI) and has taught for many years. Previously, he was a partner with Cabinet Regimbeau, an Intellectual Property Attorney and a Professional Representative with the European Patent Office.

Yannick Plétan, member of the Board of Directors since May 2021, was reappointed. Yannick Plétan holds degrees in pneumology, immunology, clinical pharmacology and pharmacokinetics - post-doctorate at INSERM and visiting professor at the University of California Davis. After practicing hospital medicine for several years, he joined the pharmaceutical industry, where he held senior R&D and medical affairs management positions for 20 years with major groups. He played a central role in the creation and worldwide development of the nicotine patch, and in the later development and launch of Champix®.

Michel Huc, member of the Board of Directors since May 2021, did not want, for personal reasons, to renew his term of office which was due to expire, in line with the Board of Directors' proposal to the general meeting.

Following this general meeting, the Board of Directors of NFL Biosciences therefore comprises:

• · Mr Ignacio Faus, Director, Chairman of the Board of Directors, Chief Executive Officer
• · Mr Bruno Lafont, Director, Chief Operating Officer
• Mr Francis Ahner, Independent Director
• · Ms Dominique Côté, Independent Director
• •

Details of the votes and participation are available on the Company website under "Shareholders General Meeting". https://www.nflbiosciences.com

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low-and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com

Contact

Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67

Calyptus – nflbiosciences@calyptus.net - +33 1 53 65 68 68